You are now leaving the Kedrion website. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion grows in North America as it completes acquisition of Prometic

Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency

read more 

CORPORATE

Kedrion stronger in North America and further committed to rare diseases

Agreement with Canadian-based Liminal BioSciences signed on June 22nd

read more 

CORPORATE

Kedrion announces the appointment of a new CEO

Val Romberg from the USA, one of the most esteemed managers in the industry

read more 

  1. CORPORATE - 23-07-2020

    COVID-19. Kedrion partners with Columbia University Irving MC

    Kedrion and Columbia University release video statements

    read more 

  2. CORPORATE - 09-04-2020

    Coronavirus, from Plasma an anti Covid-19 treatment

    Kedrion’s commitment to find a treatment from convalescent patient plasma

    read more 

  3. CORPORATE - 25-03-2020

    Letter to patient associations and scientific organizations

    Communication from Paolo Marcucci, Chairman & CEO of Kedrion

    read more 

  4. CORPORATE - 24-03-2020

    Kedrion Statement on the novel Coronavirus

    read more 

Pages

For more information please contact: [email protected]